Table 4 Inflammasome biomarkers in vitreous and serum as DR progresses
IL-1β | |||||||
|---|---|---|---|---|---|---|---|
Author, Year | Scale | Assay | Control (n) | T2DM | |||
NDR (n) | NPDR (n) | PDR (n) | |||||
Vitreous | Chen et al., 2018 [43]a | ICDRDSS | ELISA | 7 (22) | 11 (19) | 15 (20) | 23 (31) |
Zhou et al., 2012 [58] | NA | ELISA | 5.10 ± 5.46 (20) | NA | NA | 60.43 ± 27.12 (62) | |
Serum | Cvitkovic et al., 2020 [41] | NA | CBA | 16.4 ± 1.16 (35) | 17 ± 3.03 (15) | 18.6 ± 2.97 (14) | |
Koleva-Georgieva et al., 2011 [48] | ETDRS | ELISA | 0.58 ± 1.36 (38) | 1.15 ± 2.39 (11) | 0.55 ± 0.78 (16) | 4.15 ± 4.11 (11) | |
Lee et al., 2008 [49] | ETDRS | chemiluminescent immunoassay | 0.94 ± 0.81 (28) | 2.06 ± 5.94 (39) | 0.79 ± 0.67 (7) | ||
Quevedo-Martínez et al., 2021 [54] | ETDRS | CBA | 36.23 ± 6.3 (16) | 38.1 ± 6.8 (16) | 39.4 ± 4.19 (16) | 36.4 ± 5.1 (16) | |
IL-18 | |||||||
Author, Year | Scale | Assay | Control (n) | T2DM | |||
NDR (n) | NPDR (n) | PDR (n) | |||||
Vitreous | Chen et al., 2018 [43]a | ICDRDSS | ELISA | 7 (22) | 11 (19) | 15 (20) | 23 (31) |
Serum | Khalifa et al., 2009 [47] | Ophthalmologist | ELISA | 256.4 ± 13.2 (20) | 361.2 ± 7.4 (20) | 395.6 ± 12.5 (20) | 486.6 ± 14.2 (18) |
Chorostowska-Wynimko et al., 2005 [45] | Ophthalmologist | ELISA | 335 ± 93.5 (12) | NA | 453 ± 149 (12) | NA | |